{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T21:07:22Z","timestamp":1779484042940,"version":"3.53.1"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Patients with multiple myeloma (MM) undergoing treatment increasingly receive intravenous immunoglobulin (IVIG) therapy for hypogammaglobulinemia and immunosuppression. Here we sought to investigate whether IVIG administration can obscure small monoclonal (M) proteins on serum protein electrophoresis and immunofixation electrophoresis (IFE) in patients with MM.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>As a proof of concept, we performed a spiking experiment with increasing concentrations of IVIG added to a patient serum sample containing a small IgG \u03ba restricted band. We also performed a qualitative retrospective review of patient samples and present 2 instructive cases. Serum protein electrophoresis (SPE) was performed using capillary zone electrophoresis, and IFE was conducted using gel electrophoresis to assess the visibility of M-proteins before and after IVIG exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The spiking experiment demonstrated that IVIG can fully obscure a small band at clinically relevant levels. Clinical observations revealed that while an anodal \u03b3 region \u03bb restricted band remained visible, a \u03b3 region IgG \u03ba band was completely obscured by the broad, diffuse increase caused by IVIG.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Administration of IVIG may lead to false-negative SPE\/IFE interpretations by masking small monoclonal proteins. Because the detection of M-proteins is critical for distinguishing between complete response and very good partial response or identifying disease relapse, laboratory professionals must be aware of a patient\u2019s IVIG treatment status when interpreting electrophoresis results.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ajcp\/aqag050","type":"journal-article","created":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T11:18:19Z","timestamp":1776511099000},"source":"Crossref","is-referenced-by-count":0,"title":["Intravenous immunoglobulin administration may obscure the detection of small monoclonal proteins in patients with multiple myeloma"],"prefix":"10.1093","volume":"165","author":[{"given":"Johnny","family":"Le","sequence":"first","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Sasani","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyana Y","family":"Garza","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham J","family":"Qavi","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"Jin","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4560-306X","authenticated-orcid":false,"given":"Haik","family":"Mkhikian","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, University of California , Irvine, Irvine, CA,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,5,22]]},"reference":[{"key":"2026052216441060500_aqag050-B1","volume-title":"Electrophoresis and Mass Spectrometry: Monoclonal Gammopathies and Protein Disorders.","author":"Keren","year":"2024"},{"key":"2026052216441060500_aqag050-B2","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1515\/cclm-2015-0580","article-title":"Laboratory testing requirements for diagnosis and follow-up of multiple myeloma and related plasma cell dyscrasias","volume":"54","author":"Willrich","year":"2016","journal-title":"Clin Chem Lab Med"},{"key":"2026052216441060500_aqag050-B3","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1001\/jama.2022.0003","article-title":"Diagnosis and management of multiple myeloma: a review","volume":"327","author":"Cowan","year":"2022","journal-title":"JAMA"},{"key":"2026052216441060500_aqag050-B4","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1038\/s41571-025-01041-x","article-title":"EHA\u2013EMN Evidence-Based Guidelines for diagnosis, treatment and follow-up of patients with multiple myeloma","volume":"22","author":"Dimopoulos","year":"2025","journal-title":"Nat Rev Clin Oncol"},{"key":"2026052216441060500_aqag050-B5","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"2026052216441060500_aqag050-B6","doi-asserted-by":"crossref","first-page":"e1372","DOI":"10.1093\/cid\/ciab302","article-title":"Reactivation of resolved hepatitis B after daratumumab for multiple myeloma","volume":"73","author":"Lee","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2026052216441060500_aqag050-B7","doi-asserted-by":"crossref","first-page":"3163","DOI":"10.1016\/j.ymthe.2025.03.048","article-title":"Non-relapse mortality with bispecific antibodies: a systematic review and meta-analysis in lymphoma and multiple myeloma","volume":"33","author":"Tix","year":"2025","journal-title":"Mol Ther"},{"key":"2026052216441060500_aqag050-B8","doi-asserted-by":"crossref","first-page":"3069","DOI":"10.1182\/bloodadvances.2022009435","article-title":"Risk of infections associated with the use of bispecific antibodies in multiple myeloma: a pooled analysis","volume":"7","author":"Mazahreh","year":"2023","journal-title":"Blood Adv"},{"key":"2026052216441060500_aqag050-B9","doi-asserted-by":"crossref","first-page":"5898","DOI":"10.1182\/bloodadvances.2023010539","article-title":"Infections following bispecific antibodies in myeloma: a systematic review and meta-analysis","volume":"7","author":"Reynolds","year":"2023","journal-title":"Blood Adv"},{"key":"2026052216441060500_aqag050-B10","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/j.1365-2249.1991.tb05794.x","article-title":"Intravenous immunoglobulins (IVIg) in the treatment of autoimmune diseases","volume":"86","author":"Kaveri","year":"1991","journal-title":"Clin Exp Immunol"},{"key":"2026052216441060500_aqag050-B11","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1016\/j.tmrv.2009.09.011","article-title":"The use of immunoglobulin therapy for patients with primary immune deficiency: an evidence-based practice guideline","volume":"24(suppl 1)","author":"Shehata","year":"2010","journal-title":"Transfus Med Rev"},{"key":"2026052216441060500_aqag050-B12","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1136\/jitc-2020-000734","article-title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma","volume":"8","author":"Shah","year":"2020","journal-title":"J Immunother Cancer"},{"key":"2026052216441060500_aqag050-B13","doi-asserted-by":"crossref","first-page":"4720","DOI":"10.1182\/bloodadvances.2025016490","article-title":"Immunoglobulin prophylaxis should be initiated after bispecific antibody therapy in multiple myeloma, regardless of IgG levels","volume":"9","author":"Banerjee","year":"2025","journal-title":"Blood Adv"},{"key":"2026052216441060500_aqag050-B14","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1158\/2643-3230.BCD-23-0049","article-title":"IVIg use associated with ten-fold reduction of serious infections in multiple myeloma patients treated with anti-BCMA bispecific antibodies","volume":"4","author":"Lancman","year":"2023","journal-title":"Blood Cancer Discov"},{"key":"2026052216441060500_aqag050-B15","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1038\/s41408-024-01107-6","article-title":"IgG replacement in multiple myeloma","volume":"14","author":"Wonnaparhown","year":"2024","journal-title":"Blood Cancer J"},{"key":"2026052216441060500_aqag050-B16","doi-asserted-by":"crossref","first-page":"e00434","DOI":"10.1016\/j.plabm.2024.e00434","article-title":"Falsely abnormal serum protein electrophoresis after administration of intravenous immunoglobulins (IVIG): a retrospective cohort study","volume":"42","author":"Sulaiman","year":"2024","journal-title":"Pract Lab Med"},{"key":"2026052216441060500_aqag050-B17","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1093\/jalm\/jfaf134","article-title":"From suspicion of IVIG interference to diagnosis of rare syndrome","volume":"10","author":"Erol","year":"2025","journal-title":"J Appl Lab Med"},{"key":"2026052216441060500_aqag050-B18","doi-asserted-by":"crossref","first-page":"111038","DOI":"10.1016\/j.clinbiochem.2025.111038","article-title":"Decoding the interference: how therapeutic monoclonal antibodies challenge serum protein electrophoresis and immunofixation","volume":"140","author":"Milandri","year":"2025","journal-title":"Clin Biochem"},{"key":"2026052216441060500_aqag050-B19","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.clinbiochem.2017.08.013","article-title":"Recognition and management of common, rare, and novel serum protein electrophoresis and immunofixation interferences","volume":"51","author":"McCudden","year":"2018","journal-title":"Clin Biochem"},{"key":"2026052216441060500_aqag050-B20","doi-asserted-by":"crossref","first-page":"e328","DOI":"10.1016\/S1470-2045(16)30206-6","article-title":"International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma","volume":"17","author":"Kumar","year":"2016","journal-title":"Lancet Oncol"}],"container-title":["American Journal of Clinical Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag050\/68370905\/aqag050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ajcp\/article-pdf\/165\/5\/aqag050\/68370905\/aqag050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T20:44:18Z","timestamp":1779482658000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajcp\/article\/doi\/10.1093\/ajcp\/aqag050\/8690958"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5,5]]}},"URL":"https:\/\/doi.org\/10.1093\/ajcp\/aqag050","relation":{},"ISSN":["0002-9173","1943-7722"],"issn-type":[{"value":"0002-9173","type":"print"},{"value":"1943-7722","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5]]},"published":{"date-parts":[[2026,5]]},"article-number":"aqag050"}}